Tel.: +49 6221 868023
Fax: +49 6221 8680255
info@loxo.de

Pefabloc® FG, Inhibitor for Fibrinogen

Description:
Pefabloc® FG binds with a high affinity to fibrinogen, inhibits fibrin polymerization, modifies the mechanical properties of fibrin clots and can dissociate non-stabilized fibrin gels.

Application:
Pefabloc® FG is added to fibrinogen containing reaction mixtures to inhibit disturbing fibrin-related turbidity, gel formation and fibrin deposition in diagnostic and preparative procedures (e. g. measurement of thrombin generation in plasma). Pefabloc® FG is also used to inhibit fibrin formation during purification and processing of clotting factors and other plasma proteins.

Recommended Pefabloc® FG concentrations:

Application: Concentration:
Gelation prevention:  
des-AB-fibrin 0.5-2.3 mM
des-A-fibrin 2.3 mM
human plasma, HC-II test 0.5 mg/ml
bov. fibrinogen 0.2% / thrombin 0.5 U/ml    1.5 mg/ml
   
Clot liquefaction:  
des-AB-fibrin 15.0 mM
des-A-fibrin 1.0 mM

Formula: H-Gly-Pro-Arg-Pro-OH · AcOH

MW: 485.5

Solubility: readily soluble in water

Storage:
May be used by the expiry date given on the label when stored unopened, protected from moisture, in the dark, 2-8°C. Avoid contamination of the reagents by micro-organisms. Shipment of product does not require cooling during the time of transportation.

Category: Research use only

Type: Inhibitor

Product Availability: Germany, Israel and Egypt

Manufacturer: DSM Nutritional Products Ltd. Branch Pentapharm, Switzerland

For more information please click .pdf icon below.


Pefabloc FG

Inhibitor for Fibrinogen
Artikelnr.: 809901

Einheit: 1 g

Code: 099-01

Hersteller: DSM Nutritional Products Ltd. Branch Pentapharm

References:

  1. Furlan M, Rupp C, Beck E A, Svendsen L.
    Effect of calcium and synthetic peptides on fibrin polymerization. Thromb Haemost 1982; 47: 118-21.
  2. Prasa D, Svendsen L, Stürzebecher J.
    The ability of thrombin inhibitors to reduce the thrombin activity generated in plasma on extrinsic and intrinsic Activation. Thromb Haemost 1997; 77: 498-503.

Diese Webseite verwendet Cookies. Durch die Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Datenschutzerklärung X